Circulating interleukin-18: A specific biomarker for atherosclerosis-prone patients with metabolic syndrome
2011

Interleukin-18 as a Biomarker for Metabolic Syndrome

Sample size: 78 publication 10 minutes Evidence: moderate

Author Information

Author(s): Yamaoka-Tojo Minako, Tojo Taiki, Wakaume Kazuki, Kameda Ryo, Nemoto Shinji, Takahira Naonobu, Masuda Takashi, Izumi Tohru

Primary Institution: Kitasato University

Hypothesis

Circulating levels of IL-18 may enhance atherosclerosis-prone conditions in patients with metabolic syndrome.

Conclusion

IL-18 may be a useful biomarker of the clinical manifestations of metabolic syndrome and for managing cardiovascular risk factors.

Supporting Evidence

  • Increased levels of IL-18 were observed more frequently in patients with metabolic syndrome than in pre-metabolic syndrome subjects.
  • Weight loss of at least 5% significantly reduced IL-18 levels.
  • IL-18 levels were positively associated with waist circumference.
  • 89% of subjects achieved significant reductions in weight after lifestyle modifications.

Takeaway

This study found that a protein called IL-18 can help doctors tell if someone has a condition called metabolic syndrome, which can lead to heart problems. Losing weight can lower IL-18 levels and improve health.

Methodology

The study measured circulating IL-18 levels in patients with metabolic syndrome and pre-metabolic syndrome before and after lifestyle modifications.

Limitations

The study cohort was small, which may limit the generalizability of the findings.

Participant Demographics

The study included 78 Japanese outpatients with abdominal obesity, with an average age of 55.4 years.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1186/1743-7075-8-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication